First Midwest Bank Trust Division bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 25,000 shares of the company’s stock, valued at approximately $32,000.
Other large investors have also recently made changes to their positions in the company. HighTower Advisors LLC raised its position in Tonix Pharmaceuticals by 73.2% in the fourth quarter. HighTower Advisors LLC now owns 47,335 shares of the company’s stock worth $32,000 after purchasing an additional 20,000 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Tonix Pharmaceuticals in the third quarter valued at $33,000. MONECO Advisors LLC bought a new position in Tonix Pharmaceuticals in the fourth quarter valued at $35,000. Virtu Financial LLC bought a new position in shares of Tonix Pharmaceuticals in the 3rd quarter valued at about $79,000. Finally, Wells Fargo & Company MN grew its position in shares of Tonix Pharmaceuticals by 23,275.0% in the 4th quarter. Wells Fargo & Company MN now owns 187,000 shares of the company’s stock valued at $126,000 after acquiring an additional 186,200 shares during the period. 2.23% of the stock is currently owned by institutional investors.
Separately, Alliance Global Partners lifted their price objective on shares of Tonix Pharmaceuticals from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, February 25th.
Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Sunday, March 14th. The company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.02). On average, analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -0.53 earnings per share for the current fiscal year.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.